What is Cohance Lifesciences Limited's latest revenue?

Cohance Lifesciences Limited reported revenue of ₹2,269 Cr in its latest annual results, per the filed results.

What is Cohance Lifesciences Limited's latest net profit?

Cohance Lifesciences Limited reported net profit of ₹150 Cr in its latest annual results, per the filed results.

What is Cohance Lifesciences Limited's return on equity?

Cohance Lifesciences Limited posted ROE of 2.7% and ROCE of 5.4% for its latest annual results, computed from filed statements.

What is Cohance Lifesciences Limited's operating margin?

Cohance Lifesciences Limited's operating margin was 29.7% in its latest annual results, derived from filed operating expenses.

How much did Cohance Lifesciences Limited's revenue grow year-on-year?

Cohance Lifesciences Limited's revenue changed 13.9% year-on-year in its latest annual results, per the filed results.

COH

COHANCE

Name: Cohance Lifesciences Limited (COHANCE) quarterly results & financial statements
Creator: Upmazing

Cohance Lifesciences Limited

HealthcareNIFTY Smallcap 250

ISIN INE03QK01018

—

Day

52W

MCap₹17,468 Cr

weakUpmazing Score

Open chart ↗

COH

COHANCE

Cohance Lifesciences Limited

HealthcareNIFTY Smallcap 250

ISIN INE03QK01018

—

Day

52W

MCap₹17,468 Cr

weakUpmazing Score

Open chart ↗

Cohance Lifesciences Limited (COHANCE) reported revenue of ₹422 Cr and a net loss of ₹45.19 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.

COHANCE fundamentals, Fundamental score 42/100

The statements below are read from Cohance Lifesciences Limited’s filed results, 27 filed quarters and 8 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.

Latest: Q1 FY26-27 · filed Aug 6, 2026 · audited

Sales CAGR · 3Y+19.2%FY22 → FY25

Sales CAGR · 4Y+14.5%FY21 → FY25

PAT CAGR · 3Y−28.5%FY22 → FY25

PAT CAGR · 4Y−24.2%FY21 → FY25

Price · 1Y−49.2%EOD

Price CAGR · 3Y−3.5%EOD

Quarterly resultsConsolidated

₹ Cr	Jun2019	Dec2019	Mar2020	Jun2020	Sep2020	Dec2020	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026	Jun2026Latest	YoYlatest
Sales	197	179	185	238	237	275	259	264	301	392	364	339	278	354	369	348	231	220	253	258	307	402	549	1,105	545	619	422	-23.1%
	94.9	99.1	108	127	140	138	165	149	179	206	219	188	179	207	200	181	133	155	180	154	189	328	437	872	449	520	421	-3.7%
Operating profit	102	79.6	77.3	112	97.9	137	93.7	115	122	186	—	151	99.9	147	169	167	98.0	65.1	73.3	104	118	73.6	112	233	95.4	98.7	1.16	-99.0%
OPM %	51.9%	44.5%	41.8%	46.8%	41.2%	49.9%	36.2%	43.4%	40.5%	47.5%	—	44.5%	35.9%	41.5%	45.8%	48.0%	42.4%	29.6%	29.0%	40.4%	38.3%	18.3%	20.4%	21.1%	17.5%	15.9%	0.3%	-20.1 pp
Other income	2.44	4.89	5.34	5.74	0.36	4.84	3.30	5.78	5.04	64.7	16.9	11.0	10.9	13.0	11.4	10.7	19.8	14.3	17.1	14.1	15.7	10.6	14.2	29.8	6.16	-1.84	12.3	-13.5%
Interest	3.82	7.61	7.22	2.72	2.64	1.91	1.87	2.13	1.18	0.74	—	1.45	0.29	1.38	2.31	1.15	0.50	1.27	2.30	1.67	3.33	5.75	10.2	18.9	9.11	9.19	6.74	-33.8%
Depreciation	5.50	5.51	6.96	7.06	7.50	8.76	8.31	8.99	9.18	10.5	—	11.5	12.0	12.2	12.0	12.5	11.9	12.8	17.3	17.0	20.4	26.8	45.1	89.2	46.9	51.2	49.5	+9.7%
Profit before tax	113	77.7	89.4	118	96.8	147	105	133	134	239	120	149	98.5	146	166	164	105	65.5	70.8	99.5	110	51.6	62.8	147	40.6	19.9	-42.9	-168.3%
Tax %	18.6%	25.5%	17.0%	22.4%	23.5%	23.0%	21.2%	20.9%	27.6%	33.2%	57.9%	27.8%	26.8%	26.3%	25.4%	26.4%	24.5%	28.6%	24.7%	17.6%	24.1%	24.9%	26.1%	23.0%	28.5%	58.3%	n/a (loss)	—
Net profit	91.9	57.9	74.2	91.5	74.1	114	83.1	105	97.0	160	91.7	108	72.1	108	124	121	79.6	46.8	53.4	82.0	83.3	38.7	46.4	113	29.0	8.31	-45.2	-197.4%
EPS (₹)	7.22	2.27	5.83	3.60	2.91	4.46	3.27	4.13	3.81	6.29	—	4.22	2.83	4.23	—	4.74	3.13	1.84	2.10	3.23	3.26	1.65	1.28	3.22	0.96	0.51	-0.63	-149.2%

One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split · n/a (loss) = tax rate undefined on a loss↔ scroll for earlier quarters

Revenue & net profit trend

last 20 quarters

RevenueNet profit

Revenue & net profit — Consolidated20 quarters

Segment results

Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.

Forensic checksauto-scanned from the filing

Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.

How results moved the priceEOD reaction on the session the market could trade the filing

Avg absolute result-day move ±3.5%· EPS surprise: no estimates source· 4 earlier quarters have no dated filing on record

Q1'27filed Wed 5 Aug 17:48 · first tradeable session Thu 6 Auggap −2.7%close +2.2%

Q4'26filed Tue 12 May 21:03 · first tradeable session Wed 13 Maygap −7.5%close −5.8%

Q3'26filed Thu 12 Feb 21:12 · first tradeable session Fri 13 Febgap −8.6%close −10.0%

Q2'26filed Wed 12 Nov 18:37 · first tradeable session Thu 13 Novgap −1.9%close −8.8%

Q1'26filed Wed 13 Aug 17:14 · first tradeable session Thu 14 Auggap −1.6%close −7.3%

Q4'25filed Wed 28 May 18:49 · first tradeable session Thu 29 Maygap −4.9%close −3.8%

Q4'24filed Thu 30 May 17:38 · first tradeable session Fri 31 Maygap −3.5%close −2.3%

Q3'24filed Mon 5 Feb 17:19 · first tradeable session Tue 6 Febgap −7.2%close −6.0%

Q2'24filed Thu 9 Nov 17:49 · first tradeable session Fri 10 Novgap −1.2%close +4.3%

Q1'24filed Tue 8 Aug 16:14 · first tradeable session Wed 9 Auggap +0.7%close +0.6%

Q4'23filed Thu 25 May 13:41 · traded that sessiongap −0.0%close +0.6%

Q3'23filed Mon 6 Feb 13:12 · traded that sessiongap −0.1%close +1.0%

Q2'23filed Tue 8 Nov 12:42 · traded that sessiongap −2.9%close +0.4%

Q1'23filed Mon 8 Aug 13:09 · traded that sessiongap +0.5%close +3.0%

Q4'22filed Mon 9 May 13:09 · traded that sessiongap +0.5%close −2.4%

Q3'22filed Tue 8 Feb 13:14 · traded that sessiongap +0.7%close +1.9%

Q2'22filed Sat 6 Nov 12:52 · traded that sessiongap +2.8%close −1.1%

Q1'22filed Fri 13 Aug 13:12 · traded that sessiongap +0.5%close +0.1%

Q4'21filed Tue 8 Jun 13:18 · traded that sessiongap +0.8%close −3.8%

Q3'21filed Wed 10 Feb 13:24 · traded that sessiongap +0.0%close +4.4%

PeriodQ1 FY26-27BasisConsolidatedFiledAug 6, 2026Qualityaudited

Frequently Asked Questions

What is Cohance Lifesciences Limited's latest revenue?: Cohance Lifesciences Limited reported revenue of ₹2,269 Cr in its latest annual results, per the filed results.
What is Cohance Lifesciences Limited's latest net profit?: Cohance Lifesciences Limited reported net profit of ₹150 Cr in its latest annual results, per the filed results.
What is Cohance Lifesciences Limited's return on equity?: Cohance Lifesciences Limited posted ROE of 2.7% and ROCE of 5.4% for its latest annual results, computed from filed statements.
What is Cohance Lifesciences Limited's operating margin?: Cohance Lifesciences Limited's operating margin was 29.7% in its latest annual results, derived from filed operating expenses.
How much did Cohance Lifesciences Limited's revenue grow year-on-year?: Cohance Lifesciences Limited's revenue changed 13.9% year-on-year in its latest annual results, per the filed results.